The goal of the Patient-Reported Outcomes, Survey and Population Research (PROSPR) facility is to support the assessment of patient-reported outcomes and other behavioral outcomes in studies that span the continuum of research at MDACC. The PROSPR core assists investigators with multiple aspects of designing and implementing Patient Reported Outcome (PRO) data. The PROSPR core offers research support to investigators by maintaining a library of questionnaires, designing data collection procedures for PRO and behavioral studies, providing data collection services, (including face-to-face interviews or questionnaire administration in the clinic, telephone interviewing, and mailed surveys) and providing efficient data entry of the collected PRO data. The PROSPR data management team develops information systems to assist investigators in managing study participants and data. The team also develops recruitment and participant tracking databases, creates data entry databases for PRO questionnaire data that have double entry systems for accuracy checking, as well as built-in range and validity checks, and provides analysis datasets for project statisticians, which includes cleaning and scoring the data. The data management team can create tools for automating the assignment of participants to study conditions, for a simple randomization or a form of adaptive randomization called minimization, which is similar to stratification. The PROSPR core facility is housed in 688 square feet of office space in the Cancer Prevention Building within the Department of Behavioral Science. The facility has 9 staff members, which include the director, co-director, core manager, 2 research coordinators, a statistical analyst, and 3 data managers. Over the past 4 years, the PROSPR core has delivered over 9,400 hours of service to 87 users, of which 47% have been peerreviewed funded. In this period, the PROSPR core has provided assistance to 15 programs;Behavioral and Health Disparities accounted for 56% of the utilization, followed by GU, Gynecological, Gl and Breast Cancers which account for 24%. In the future, the PROSPR core intends to 1) offer web-based surveys, and computer adaptive testing (CAT) as the technology becomes available;2) to more fully utilize CaBIG, which is expanding to include more population science research and;3) to develop training opportunities for investigators and research staff to increase their skills and knowledge related to research involving PRO data.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-37
Application #
8379491
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
37
Fiscal Year
2012
Total Cost
$233,561
Indirect Cost
$81,893
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Viswanathan, Chitra; Faria, Silvana; Devine, Catherine et al. (2018) [18F]-2-Fluoro-2-Deoxy-D-glucose-PET Assessment of Cervical Cancer. PET Clin 13:165-177
Debnam, James M; Chi, Tzehping L; Ketonen, Leena et al. (2018) Superiority of Multidetector Computed Tomography With 3-Dimensional Volume Rendering Over Plain Radiography in the Assessment of Spinal Surgical Instrumentation Complications in Patients With Cancer. J Comput Assist Tomogr :
Patel, V K; Lamothe, B; Ayres, M L et al. (2018) Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia 32:920-930
Ravandi, Farhad; Ritchie, Ellen K; Sayar, Hamid et al. (2018) Phase 3 results for vosaroxin/cytarabine in the subset of patients ?60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica 103:e514-e518
Assi, Rita; Kantarjian, Hagop M; Kadia, Tapan M et al. (2018) Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 124:2758-2765
Yam, Clinton; Murthy, Rashmi K; Valero, Vicente et al. (2018) A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs 36:299-306
Lacourt, Tamara E; Vichaya, Elisabeth G; Escalante, Carmen et al. (2018) An effort expenditure perspective on cancer-related fatigue. Psychoneuroendocrinology 96:109-117
Ni, Haiwen; Shirazi, Fazal; Baladandayuthapani, Veerabhadran et al. (2018) Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res 24:6408-6420
Neelapu, Sattva S; Tummala, Sudhakar; Kebriaei, Partow et al. (2018) Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol 15:218
Cortes, Jorge; Tamura, Kenji; DeAngelo, Daniel J et al. (2018) Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer 118:1425-1433

Showing the most recent 10 out of 12418 publications